228 related articles for article (PubMed ID: 24700598)
1. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors.
Meaney CJ; Hynicka LM; Tsoukleris MG
Pharmacotherapy; 2014 Jul; 34(7):653-61. PubMed ID: 24700598
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
Burgess LD; Drew RH
Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041
[TBL] [Abstract][Full Text] [Related]
3. Incidence and predictors of vancomycin-associated nephrotoxicity.
Moh'd H; Kheir F; Kong L; Du P; Farag H; Mohamad A; Zurlo JJ
South Med J; 2014 Jun; 107(6):383-8. PubMed ID: 24945176
[TBL] [Abstract][Full Text] [Related]
4. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.
Cano EL; Haque NZ; Welch VL; Cely CM; Peyrani P; Scerpella EG; Ford KD; Zervos MJ; Ramirez JA; Kett DH;
Clin Ther; 2012 Jan; 34(1):149-57. PubMed ID: 22284995
[TBL] [Abstract][Full Text] [Related]
5. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA
Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221
[TBL] [Abstract][Full Text] [Related]
6. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.
Jeffres MN; Isakow W; Doherty JA; Micek ST; Kollef MH
Clin Ther; 2007 Jun; 29(6):1107-15. PubMed ID: 17692725
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*.
Hanrahan TP; Harlow G; Hutchinson J; Dulhunty JM; Lipman J; Whitehouse T; Roberts JA
Crit Care Med; 2014 Dec; 42(12):2527-36. PubMed ID: 25083977
[TBL] [Abstract][Full Text] [Related]
8. Lowered Risk of Nephrotoxicity through Intervention against the Combined Use of Vancomycin and Tazobactam/Piperacillin: A Retrospective Cohort Study.
Oda K; Hashiguchi Y; Katanoda T; Nakata H; Jono H; Saito H
Microbiol Spectr; 2021 Sep; 9(1):e0035521. PubMed ID: 34346742
[TBL] [Abstract][Full Text] [Related]
9. The Relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis.
Horey A; Mergenhagen KA; Mattappallil A
Ann Pharmacother; 2012 Nov; 46(11):1477-83. PubMed ID: 23073306
[TBL] [Abstract][Full Text] [Related]
10. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
Lodise TP; Patel N; Lomaestro BM; Rodvold KA; Drusano GL
Clin Infect Dis; 2009 Aug; 49(4):507-14. PubMed ID: 19586413
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy.
Ingram PR; Lye DC; Tambyah PA; Goh WP; Tam VH; Fisher DA
J Antimicrob Chemother; 2008 Jul; 62(1):168-71. PubMed ID: 18334494
[TBL] [Abstract][Full Text] [Related]
12. Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin.
Masuda N; Maiguma T; Komoto A; Haruki Y; Sugiyama T; Kondo S; Teshima D
Int J Clin Pharmacol Ther; 2015 Apr; 53(4):284-91. PubMed ID: 25740266
[TBL] [Abstract][Full Text] [Related]
13. Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 μg/ml in a pediatric intensive care unit.
Cies JJ; Shankar V
Pharmacotherapy; 2013 Apr; 33(4):392-400. PubMed ID: 23471688
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.
Hermsen ED; Hanson M; Sankaranarayanan J; Stoner JA; Florescu MC; Rupp ME
Expert Opin Drug Saf; 2010 Jan; 9(1):9-14. PubMed ID: 20021290
[TBL] [Abstract][Full Text] [Related]
15. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system.
Pogue JM; Lee J; Marchaim D; Yee V; Zhao JJ; Chopra T; Lephart P; Kaye KS
Clin Infect Dis; 2011 Nov; 53(9):879-84. PubMed ID: 21900484
[TBL] [Abstract][Full Text] [Related]
16. Nephrotoxicity associated with intravenous colistin in critically ill patients.
Doshi NM; Mount KL; Murphy CV
Pharmacotherapy; 2011 Dec; 31(12):1257-64. PubMed ID: 22122186
[TBL] [Abstract][Full Text] [Related]
17. Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime.
Moenster RP; Linneman TW; Finnegan PM; Hand S; Thomas Z; McDonald JR
Clin Microbiol Infect; 2014 Jun; 20(6):O384-9. PubMed ID: 24118354
[TBL] [Abstract][Full Text] [Related]
18. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.
Lodise TP; Lomaestro B; Graves J; Drusano GL
Antimicrob Agents Chemother; 2008 Apr; 52(4):1330-6. PubMed ID: 18227177
[TBL] [Abstract][Full Text] [Related]
19. Retrospective review of vancomycin-induced nephrotoxicity in patients with leukemia.
Fullmer A; McCue D; Feng C
J Oncol Pharm Pract; 2014 Dec; 20(6):403-8. PubMed ID: 24177356
[TBL] [Abstract][Full Text] [Related]
20. Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring.
Han HK; An H; Shin KH; Shin D; Lee SH; Kim JH; Cho SH; Kang HR; Jang IJ; Yu KS; Lim KS
Ther Drug Monit; 2014 Oct; 36(5):606-11. PubMed ID: 24577126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
